[1]孙霄,冯思哲,梁国标,等.双镜联合手术治疗巨大侵袭性垂体腺瘤的疗效分析[J].中国临床神经外科杂志,2023,28(09):545-548.[doi:10.13798/j.issn.1009-153X.2023.09.001]
　SUN Xiao,FENG Si-zhe,LIANG Guo-biao,et al.Efficacy of transcranial surgery combined with trans-sphenoidal endoscopic surgery for patients with giant invasive pituitary adenoma[J].,2023,28(09):545-548.[doi:10.13798/j.issn.1009-153X.2023.09.001]
点击复制

双镜联合手术治疗巨大侵袭性垂体腺瘤的疗效分析()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
28
期数:
2023年09期
页码:
545-548
栏目:
论著
出版日期:
2023-09-30

文章信息/Info

Title:
Efficacy of transcranial surgery combined with trans-sphenoidal endoscopic surgery for patients with giant invasive pituitary adenoma
文章编号:
1009-153X（2023）09-0545-04
作者:
孙霄; 冯思哲; 梁国标; 韩松; 孙晓宇; 白杨; 李心宁; 王格宇; 孙瑛玮
110016沈阳，北部战区总医院神经外科（孙霄、冯思哲、梁国标、韩松、孙晓宇、白杨、李心宁、王格宇、孙瑛玮）
Author(s):
SUN Xiao;  FENG Si-zhe;  LIANG Guo-biao;  HAN Song;  SUN Xiao-yu;  BAI Yang;  LI Xin-ning;  WANG Ge-yu;  SUN Ying-wei
Department of Neurosurgery, The General Hospital of Northern Theater Command, 110016
关键词:
巨大侵袭性垂体腺瘤; 经鼻蝶入路; 神经内镜手术; 经颅手术; 双镜联合手术; 疗效
Keywords:
Giant invasive pituitary adenomas;  Transcranial surgery (TCS);  Transsphenoidal endoscopic surgery (EETS);  Efficacy
分类号:
R 739.41; R 651.1+1
DOI:
10.13798/j.issn.1009-153X.2023.09.001
文献标志码:
A
摘要:
目的 探讨经颅手术联合经鼻蝶入路神经内镜手术治疗巨大（>4 cm）侵袭性垂体腺瘤的疗效。方法 回顾性分析2017年9月~2023年3月双镜联合手术治疗的18例巨大侵袭性垂体腺瘤的临床资料，观察术后肿瘤切除率、激素缓解情况以及颅内感染、术区出血等并发症发生情况。结果 肿瘤全切除14例（77.8%），次全切除4例（22.2%）。手术时间平均（5.2±1.4）h。术后内分泌复查：术前泌乳素增高的11例中，术后恢复正常8例，无明显变化3例；术前1例促肾上腺皮质激素增高，术后恢复正常。术后出现肾上腺功能减退2例（11.1%）、暂时性尿崩症2例（11.1%）、远隔部位急性硬膜外血肿1例、脑脊液漏1例，无颅内感染、术区出血。术后随访3~24个月，平均（10.1±9.1）个月；1例次全切除术后复发（肿瘤直径约1 cm），经γ刀治疗后未见明显生长，未再次手术治疗。头痛缓解率为78.6%（11/14），视力及视野改善率为85.7%（12/14）。结论 经颅显微镜下手术联合经鼻蝶入路神经内镜手术治疗巨大侵袭性垂体腺瘤是安全、有效、可行的。巨大侵袭性垂体腺瘤经术前充分评估难以从单一入路切除时，可选择双镜联合手术，争取一期安全切除肿瘤。
Abstract:
Objective To investigate the efficacy of transcranial surgery (TCS) combined with transsphenoidal endoscopic surgery (TSES) for patients with giant (>4 cm) invasive pituitary adenoma. Methods The clinical data of 18 patients with giant invasive pituitary adenoma, who underwent TCS combined with TSES from September 2017 to March 2023, were retrospectively analyzed. The postoperative tumor resection rate, hormone remission, intracranial infection, operative area bleeding, and other complications were observed. Results Total tumor resection was achieved in 14 patients (77.8%), and subtotal in 4 (22.2%). The average operation time was (5.2±1.4) hours. Postoperative endocrine reexamination showed that of 11 patients with increased prolactin before surgery, 8 patients returned to normal and 3 did not change significantly after surgery. Additionally, one patient with increased adrenocorticotropic hormone before surgery returned to normal after the procedure. Adrenal insufficiency occurred in 2 patients (11.1%), temporary diabetes insipidus in 2 (11.1%), acute epidural hematoma at a remote site in 1, and cerebrospinal fluid leakage in 1. There were no intracranial infection or operative area bleeding. Follow-up ranged from 3 months to 24 months with an average of (10.1±9.1) months. One patient recurred after subtotal resection (tumor diameter approximately 1 cm), which was subsequently treated using gamma knife therapy without any significant growth thereafter. The headache remission rate was 78.6% (11/14), and the improvement rate for vision and visual field reached up to 85.7% (12/14). Conclusions TCS combined with TSES is a safe, effective, and feasible approach for treating giant invasive pituitary adenomas. When a giant invasive pituitary adenoma is difficult to be resected from a single approach after adequate preoperative evaluation, combined surgery can be selected to achieve one-stage safe tumor resection.

参考文献/References:

[1] 张世彬，陈图南，吴国材，等. 神经导航辅助下扩大经鼻蝶入路神经内镜手术切除巨大侵袭性垂体腺瘤1例[J]. 中国临床神经外科杂志，2023，28（3）：219-220.
[2] 王云锋，闫惠颖，杭春华，等. 经鼻蝶入路神经内镜手术联合眶上外侧入路显微手术治疗大型垂体腺瘤[J]. 中国临床神经外科杂志，2022，27（12）：961-963.
[3] 佚　名. 中国难治性垂体腺瘤诊治专家共识（2019）[J]. 中华医学杂志，2019，99（19）：6.
[4] 徐志明，李胜利，李　彤，等. 假包膜外切除术治疗无功能型垂体腺瘤的疗效[J]. 中国临床神经外科杂志，2022，27（5）：382-383.
[5] LUZZI S, GIOTTA LUCIFERO A, RABSKI J, et al. The party wall: redefining the indications of transcranial approaches for giant pituitary adenomas in endoscopic era[J]. Cancers (Basel), 2023, 15(8): 2235.
[6] 李　兵，张溢华，黄　平，等. 垂体腺瘤术后复发的危险因素分析[J]. 中国临床神经外科杂志，2020，25（7）：436-438.
[7] 张溢华，徐伦山，许民辉. 经鼻蝶入路神经内镜手术治疗侵袭性垂体腺瘤的进展[J]. 中国临床神经外科杂志，2021，26（5）：385-387.
[8] 康盈盈，朱丽娟，王文节，等. 垂体影像学特征在无功能性垂体腺瘤术后内分泌功能评估中的作用[J]. 中国临床神经外科杂志，2022，27（06）：440-443+446.
[9] AVERSA A, NAJJAR J, AL-MEFTY O. Transcranial approach to invasive giant pituitary adenoma: 2-dimensional operative video [J]. Oper Neurosurg (Hagerstown), 2022, 23: e160-e161.
[10] 段高伟，宋志斌，王　龙，等. 巨大型垂体腺瘤手术治疗新进展[J]. 世界最新医学信息文摘，2019，19（59）：50-52.
[11] MAKARENKO S, ALZAHRANI I, KARSY M, et al. Out-comes and surgical nuances in management of giant pituitary adenomas: a review of 108 cases in the endoscopic era[J]. J Neurosurg, 2022. doi: 10.3171/2021.10.JNS21659. Online ahead of print.
[12] 徐　佳，王彬彬，王协锋，等. 游离鼻粘膜瓣在垂体腺瘤经鼻入路神经内镜手术鞍底重建中的应用[J]. 中国临床神经外科杂志，2022，27（12）：1013-1015.
[13] MUHSEN BA, NAJERA E, CAPPELLO Z, et al. Endoscopic endonasal approach for resection of giant nonfunctional pituitary adenoma [J]. Clin Neurol Neurosurg, 2023, 230: 107725.
[14] FAVIER V, LE CORRE M, SEGNARBIEUX F, et al. Endo-scopic subperichondrial transseptal transsphenoidal approach is safe and efficient for non-extended pituitary surgery[J]. Eur Arch Otorhinolaryngol, 2020, 277: 1079-1087.
[15] 贺　虎，王　飞，凌士营. 经鼻蝶神经内镜与显微镜下切除垂体瘤的安全性与疗效对比[J]. 立体定向和功能性神经外科杂志，2022，35（1）：12-17.
[16] KINO H, ITO Y, AKUTSU H, et al. Combined endoscopic endonasal and bilateral subfrontal approach for a nonfunctioning pituitary adenoma associated with an internal carotid artery-superior hypophyseal artery aneurysm[J]. World Neurosurg, 2020, 134: 297-301.
[17] DI SOMMA A, GUIZZARDI G, VALLS CUSINé C, et al. Combined endoscopic endonasal and transorbital approach to skull base tumors: a systematic literature review[J]. J Neurosurg Sci, 2022, 66: 406-412.
[18] KUGA D, TODA M, OZAWA H, et al. Endoscopic endonasal approach combined with a simultaneous transcranial approach for giant pituitary tumors[J]. World Neurosurg, 2019, 121: 173-179.

相似文献/References:

[1]王亚平　贾晓雄　王　珺　王林林　谭溢涛　马德得　夏鹤春.神经内镜下与显微镜下经鼻蝶入路手术切除垂体腺瘤的疗效对比分析[J].中国临床神经外科杂志,2016,(03):145.[doi:10.13798/j.issn.1009-153X.2016.03.004]
　WANG Ya-ping,JIA Xiao-xiong,WANG-Jun,et al.Resection of pituitary adenomas by endoscopic and microscopic surgery via transnasal transsphenoidal approach: a comparative analysis[J].,2016,(09):145.[doi:10.13798/j.issn.1009-153X.2016.03.004]
[2]线春明　张　强　杨　鹏.垂体脓肿的诊治分析：附3例报告并文献复习[J].中国临床神经外科杂志,2016,(01):38.[doi:10.13798/j.issn.1009-153X.2016.01.013]
[3]甘志强　龚　杰　姚国杰　张　戈　黄　成　秦　汉　陈大瑜　马廉亭.PACS系统影像测量在经鼻蝶入路手术治疗鞍区病变中的价值[J].中国临床神经外科杂志,2015,(08):463.[doi:10.13798/j.issn.1009-153X.2015.08.006]
　GAN Zhi-qiang,GONG Jie,YAO Guo-jie,et al.Value of measuring the anatomic markers related to operation with PACS software to transsphenoidal surgery for sellar lesions[J].,2015,(09):463.[doi:10.13798/j.issn.1009-153X.2015.08.006]
[4]王　璨　喻军华　黄锦峰　陈志勇　刘　斌　袁学刚　吴新宇.经鼻蝶入路显微手术切除垂体腺瘤36例[J].中国临床神经外科杂志,2015,(09):547.[doi:10.13798/j.issn.1009-153X.2015.09.012]
[5]苏卢海　张世渊　胡昌辰　沈　波.神经导航辅助内镜下经鼻蝶入路手术治疗垂体腺瘤的疗效观察[J].中国临床神经外科杂志,2015,(09):549.[doi:10.13798/j.issn.1009-153X.2015.09.013]
[6]王重韧　赵　明　徐　欣　尤　宇　韩　磊　赵四军.症状型Rathke裂隙囊肿的临床特征及外科治疗（附13例报告）[J].中国临床神经外科杂志,2015,(04):214.[doi:10.13798/j.issn.1009-153X.2015.04.007]
　WANG Chong-ren,ZHAO Ming,XU Xin,et al.Clinical features and surgical treatment of symptomatic Rathke cleft cysts (report of 13 cases)[J].,2015,(09):214.[doi:10.13798/j.issn.1009-153X.2015.04.007]
[7]赵建平,张红波,穆林森,等.内镜下经鼻蝶术后迟发性鼻出血的护理[J].中国临床神经外科杂志,2016,(12):794.[doi:10.13798/j.issn.1009-153X.2016.12.025]
[8]郑　涛　吕文海　陈　隆　王　元　贺世明　高国栋.经鼻蝶入路内镜下切除垂体腺瘤术后脑脊液漏的治疗[J].中国临床神经外科杂志,2017,(01):46.[doi:10.13798/j.issn.1009-153X.2017.01.018]
[9]吴黎琨,王雪玲,李慧,等.神经导航辅助下经鼻蝶入路切除鞍内型颅咽管瘤的围手术期护理[J].中国临床神经外科杂志,2017,(07):512.[doi:10.13798/j.issn.1009-153X.2017.07.026]
[10]毋江 杨红利 解旭鹏 王甲光.经鼻蝶入路垂体腺瘤切除术后严重颅内感染合并脑积水2例[J].中国临床神经外科杂志,2017,(10):734.[doi:10.13792017.09/j.issn.1009-153X.2017.10.025]

备注/Memo

备注/Memo:
（2023-06-12收稿，2023-08-01修回）
基金项目：辽宁省科学技术计划项目（2021JH2/10300116；2022JH2/101500023）
通讯作者：冯思哲，E-mail：fengsizhe@sohu.com
更新日期/Last Update: 2022-09-30